Serotonergic Responsivity in Obsessive-Compulsive Disorder: Effects of Chronic Clomipramine Treatment

Archives of General Psychiatry

Volumn 45, Issue 2, 1988, Pages 167-172

  Zohar, Joseph ^a   Insel, Thomas R ^a   Zohar Kadouch, Rachel C ^a   Hill, James L ^a   Murphy, Dennis L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE;

ADULT; ANXIETY; CLINICAL ARTICLE; COMPULSION; HUMAN; OBSESSION; PSYCHOLOGICAL ASPECT;

ADULT; AGED; BRAIN CHEMISTRY; CLINICAL TRIALS; CLOMIPRAMINE; DOUBLE-BLIND METHOD; FEMALE; HUMAN; HYDROCORTISONE; MALE; MIDDLE AGE; OBSESSIVE-COMPULSIVE DISORDER; PIPERAZINES; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; RANDOM ALLOCATION; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0023830602     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1988.01800260081011     Document Type: Article

References (40)

1. Thorén P, Åsberg M, Cronholm B, Jörnestedt L, Traskman L: Clomipramine treatment of obsessive-compulsive disorder: I. A controlled clinical trial. Arch Gen Psychiatry 1980;37:1281-1285.
2. Ananth J, Pecknold JC, van der Steen N, Engelsmann F: Double blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol Biol Psychiatry 1980;5:257-264.
3. Volavka J, Neziroglu F, Yaryura-Tobias JA: Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Res 1985;14:83-91.
4. Zohar J, Insel TR: Obsessive-compulsive disorder: Psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry 1987;22:677-687.
5. Marks IM, Stern R, Mawson D, Cobb J, McDonald R: Clomipramine and exposure for obsessive compulsive rituals. Br J Psychiatry 1980;136:1-25.
6. Maudsley H: The Pathology of the Mind. New York, Macmillan Publishing Co Inc, 1985.
7. Flament MF, Rapoport JL, Berg CJ, Sceery W, Kilts C, Mellstram B, Linnoila M: Clomipramine treatment of childhood obsessive compulsive disorder: A double-blind controlled study. Arch Gen Psychiatry 1985;42:977-983.
8. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M: Obsessive-compulsive disorder: A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983;40:605-612.
9. Kahn RS, Westenberg HGM, Jolles J: Zimeldine treatment of obsessive-compulsive disorder. Acta Psychiatr Scand 1984;69:259-261.
10. Prasad A: A double blind study of imipramine versus zimeldine in treatment of obsessive compulsive neurosis. Pharmacopsychiatry 1984;17:61-62.
11. Fontaine R, Chouinard G: Antiobsessive effect of fluoxetine. Am J Psychiatry 1985;142:989.
12. Turner SM, Jacob RG, Beidel DC, Himmelhoch J: Fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1985;5:207-212.
13. Goodman WK, Price LH, Rasmussen SA, Charney DS, Woods SN, Heninger GRL: Evidence for abnormal serotonergic function in obsessive-compulsive disorder, abstract 317.6. Abstracts of the 16th Annual Meeting of the Society for Neuroscience, Washington, DC, Nov 9-14, 1986.
14. Zohar J, Insel TR: Biological approaches to diagnosis and treatment of obsessive-compulsive disorder, in Risch SC, Janowsky D (eds): The Art of Psychopharmacology. New York, Guilford Press, in press.
15. Samanin R, Mennini T, Ferraris A: m-Chlorophenylpiperazine: A central serotonin agonist causing powerful anorexia in rats. Naunyn Schmiedebergs Arch Pharmacol 1979;308:159-163.
16. Fuller RW, Mason NR, Molloy BP: Structural relationships in the inhibition of [3H]-serotonin binding to rat brain membranes in vitro by 1-phenylpiperazines. Biochem Pharmacol 1980;29:833-835.
17. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL: Serotonergic responsivity in obsessive-compulsive disorder: Comparison of patients and healthy controls. Arch Gen Psychiatry 1987;44:946-951.
18. Ross SB, Renyi AL: Inhibition of the neuronal uptake of 5-hydroxytryptamine and noradrenaline in rat brain by (Z) and (E)-3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridyl) allylamines and their secondary analogues. Neuropharmacology 1977;16:57-63.
19. Benfield DP, Harris CM, Luscombe DK: Some pharmacological aspects of desmethylclomipramine. Postgrad Med J 1980;56:13-18.
20. Fuller RW, Snoddy HD, Mason NR, Owen JE: Disposition and pharmacological effects of m-chlorophenylpiperazine in rats. Neuropharmacology 1981;20:155-162.
21. Invernizzi R, Cotecchia S, DeBlasi A, Mennini T, Pataccini R, Samanin R: Effects of m-chlorophenylpiperazine on receptor binding and brain metabolism of monoamines in rats. Neurochem Int 1981;3:239-244.
22. Rokosz-Pelc A, Antkiewics-Michaluk L, Vetulai J: 5-Hydroxytryptamine-like properties of m-chlorophenylpiperazine: Comparison with quipazine. J Pharm Pharmacol 1980;32:220-222.
23. Mennini T, Poggasi E, Caccia S, Bendotti C, Borsini F, Samanin R: Adaptive changes in central serotonin receptors after long-term treatment in rats, in Littauer UZ, Dudai Y, Silman I (eds): Neurotransmitters and Their Receptors. New York, John Wiley & Sons Inc, 1980, pp 101-108.
24. Vetulani J, Sansone M, Bednarczyk B, Hano J: Different effects of 3-chlorophenylpiperazine on locomotor activity and acquisition of conditioned avoidance response in different strains of mice. Naunyn Schmiedebergs Arch Pharmacol 1982;319:271-274.
25. Maj J, Lewandowska A: Central serotoninmimetic action of phenylpiperazines. Pol J Pharmacol Pharm 1980;32:495-504.
26. Aloi JA, Insel TR, Mueller EA, Murphy DL: Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys. Life Sci 1984;34:1325-1331.
27. Quattrone A, Schettini G, Anunziato L, DeRenzo G: Pharmacological evidence of super-sensitivity of central serotonergic receptors involved in control of prolactin secretion. Eur J Pharmacol 1981;76:9-13.
28. Cohen RM, Aulakh CS, Murphy DL: Long-term clorgyline treatment antagonizes the eating and motor function responses to m-chlorophenylpiperazine. Eur J Pharmacol 1983;94:175-179.
29. Mueller EA, Murphy DL, Sunderland T: Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist, in humans. J Clin Endocrinol Metab 1985;61:1-6.
30. Mueller EA, Murphy DL, Sunderland T: Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: Evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology 1986;89:388-391.
31. American Psychiatric Association, Committee on Nomenclature and Statistics: Diagnostic and Statistical Manual of Mental Disorders, ed 3. Washington, DC, American Psychiatric Association, 1980.
32. Murphy DL, Pickar D, Alterman IS: Methods for the quantitative assessment of depressive and manic behavior, in Burdock EI, Sudilovsky A, Gershon S (eds): The Behavior of Psychiatric Patients. New York, Marcel Dekker Inc, 1982, pp 355-391.
33. Van Kammen DP, Murphy DL: Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia 1975;44:215-224.
34. Cole EN, Groom GV, Link J, O'Flanagan PM, Seldrup J: Plasma prolactin concentrations in patients on clomipramine. Postgrad Med J 1976;52:93-100.
35. Kato Y, Matsushita N, Ohta H, Tojo K, Shimatso A, Imura H: Regulation of prolactin secretion, in Imura H (ed): The Pituitary Gland. New York, Raven Press, 1985, pp 261-278.
36. Jacobs LS, Snyder PJ, Utiger RD, Daughaday WH: Prolactin response to thyrotropin-releasing hormone in normal subjects. J Clin Endocrinol Metab 1973;36:1069.
37. Wamsley JK, Byerley WF, McCabe RT, McConnell EJ, Dawson TM, Grosser BI: Receptor alterations associated with serotonergic agents: An autoradiographic analysis. J Clin Psychiatry 1987;48:19-25.
38. Thorén P, Åsberg M, Bertilsson L, Mellström B, Sjöqvist F, Träskman L: Clomipramine treatment of obsessive-compulsive disorder: II. Biochemical aspects. Arch Gen Psychiatry 1980;37:1289-1294.
39. Flament MF, Rapoport JL, Murphy DL, Lake CR, Berg CJ: Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 1987;44:219-225.
40. Zohar J, Insel TR: Drug treatment of obsessive-compulsive disorder. J Affective Disord, in press.